Family medicine clinicians initiating or managing GLP-1 and dual GIP/GLP-1 receptor agonist therapy need to recognize that rapid weight loss with these agents may disproportionately reduce lean muscle mass, which carries downstream risks including sarcopenia, reduced functional capacity, and impaired glucose metabolism. Monitoring tools such as DEXA-based body composition analysis or validated functional assessments like grip strength and gait speed become clinically relevant in this context, particularly for older adults and those with baseline low muscle mass. Prescribers should consider proactive co-interventions including resistance exercise programming and adequate dietary protein intake as standard adjuncts to GLP-1 therapy, not afterthoughts, given that preserving skeletal muscle is essential to the long-term metabolic and functional outcomes these medications are intended to support.
Researchers at the University of North Carolina examined the effects of incretin-based therapies, specifically semaglutide and tirzepatide, on body composition during weight loss, with a focus on the proportion of lean mass lost relative to total weight reduction. The investigation sought to characterize whether the weight loss achieved with these agents reflected a favorable fat-preferential pattern or whether skeletal muscle mass was being disproportionately affected in treated patients.
The findings indicated that patients using these GLP-1 and GLP-1/GIP receptor agonists experienced rates of lean mass loss that exceeded what would typically be expected from caloric restriction alone or from other weight loss interventions. While total weight reduction with these agents is well established and clinically meaningful, the data suggest that a substantial portion of that loss may be coming from skeletal muscle rather than adipose tissue, raising questions about the net metabolic and functional benefit for patients over time.
For prescribers, these findings carry direct practical implications. Skeletal muscle mass is a primary determinant of insulin sensitivity, basal metabolic rate, functional independence, and long-term cardiometabolic resilience. Patients on semaglutide or tirzepatide, particularly those who are older, sedentary, or already sarcopenic, may warrant proactive monitoring of body composition rather than relying on weight or BMI alone as outcome measures. Resistance training protocols and adequate dietary protein intake, generally cited in the range of 1.2 to 1.6 grams per kilogram of body weight daily, should be discussed as concurrent interventions at the time of prescribing rather than as afterthoughts, in order to preserve lean mass and protect the functional gains that meaningful weight reduction is intended to provide.
GLP-1 receptor agonists such as semaglutide and tirzepatide are effective for weight reduction, but research from UNC suggests that a disproportionate share of that weight loss may come from lean muscle mass rather than fat alone. This pattern of muscle loss, sometimes called sarcopenic obesity risk, is a clinically meaningful concern because preserving muscle mass is critical for metabolic health, functional independence, and long-term outcomes. Clinicians prescribing these agents should routinely monitor body composition, not just total body weight, to get a clearer picture of treatment response. In family medicine practice, proactively counseling patients to engage in resistance training and maintain adequate protein intake throughout GLP-1 therapy can help offset muscle loss and improve the overall quality of their weight loss results.
“What this UNC data reinforces for me clinically is something I have been counseling patients about for some time now: the scale going down does not automatically mean the right tissue is going down. Incretin-based therapies like semaglutide and tirzepatide are extraordinarily effective at driving weight loss, but without intentional protein optimization and resistance training built into the treatment plan, a meaningful portion of that loss can come from lean mass rather than adipose tissue. The long-term consequences of that trade-off, including reduced metabolic rate, functional decline, and sarcopenic obesity, are not trivial. In practice, this means I now have a direct, upfront conversation with every patient starting a GLP-1 or dual agonist therapy about what we are actually trying to preserve, and we track body composition, not just weight, as a core outcome metric from day one.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What are GLP-1 medications like semaglutide and tirzepatide actually designed to do?
These medications were originally developed to help manage blood sugar in type 2 diabetes by mimicking natural gut hormones called incretins. They also reduce appetite and slow digestion, which leads to significant weight loss in many patients. Doctors now prescribe them for both diabetes management and obesity treatment.
Is losing muscle during weight loss on GLP-1 therapy a new concern?
Some degree of muscle loss occurs with any significant weight loss, but recent research from UNC suggests the proportion of muscle lost with GLP-1 medications may be higher than expected. This finding has prompted clinicians to look more carefully at body composition changes, not just total weight, in patients on these therapies. It is an active and important area of ongoing investigation.
How can I tell if I am losing muscle and not just fat while on semaglutide or tirzepatide?
Standard scales only measure total body weight and cannot distinguish fat from muscle. A DEXA scan or bioelectrical impedance analysis can give your doctor a clearer picture of your body composition over time. Ask your physician about tracking these measurements at the start of therapy and at regular intervals.
Why does losing muscle matter if I am losing weight overall?
Muscle is metabolically active tissue that supports your resting metabolism, physical strength, blood sugar regulation, and long-term functional independence. Losing a disproportionate amount of muscle can make weight regain more likely and may increase the risk of falls and weakness, especially in older adults. Preserving muscle is considered just as important as losing fat for overall health outcomes.
Can I prevent muscle loss while taking a GLP-1 medication?
Resistance exercise and adequate protein intake are the two most evidence-supported strategies for preserving muscle during any weight loss program. Your doctor or a registered dietitian can help you set protein targets appropriate for your body weight and activity level. Starting or maintaining a strength training routine during GLP-1 therapy is strongly encouraged.
How much protein should I be eating while on semaglutide or tirzepatide?
General clinical guidance for patients actively losing weight suggests a minimum of 1.2 to 1.6 grams of protein per kilogram of body weight per day, though individual needs vary. Because GLP-1 medications significantly reduce appetite, many patients struggle to meet protein goals without intentional planning. A registered dietitian familiar with GLP-1 therapy can help you build a practical eating strategy.
Should I be concerned if I feel weaker or more fatigued on my GLP-1 medication?
Fatigue and reduced strength during active weight loss can reflect muscle loss, caloric restriction, or both, and should be reported to your physician. Your doctor may order labs, adjust your dose, or recommend changes to your diet and exercise plan. Do not assume these symptoms are simply a normal side effect to push through without evaluation.
Will stopping my GLP-1 medication help me keep my muscle mass?
Stopping the medication without a plan often leads to weight regain, which does not automatically restore lost muscle in the same proportions. The more important strategy is to protect muscle actively while on the medication through exercise and nutrition rather than relying on stopping the drug. Any decision to discontinue therapy should be made collaboratively with your prescribing physician.
Does this research mean GLP-1 medications are unsafe or not worth taking?
No single study changes the overall benefit-risk profile of these medications, which have strong evidence supporting improvements in cardiovascular outcomes, blood sugar control, and obesity-related disease. The UNC findings highlight an important consideration that should be part of clinical monitoring and patient counseling, not a reason to avoid treatment. Your doctor can help you weigh the benefits and risks based on your individual health history.
Should my doctor be monitoring my muscle mass while I am on GLP-1 therapy?
Ideally, clinicians prescribing these medications should track more than just weight and BMI over time. Baseline and follow-up body composition assessments, along with attention to functional strength and protein intake, represent a more complete approach to managing patients on GLP-1 therapy. If your current care plan does not include these elements, it is a reasonable and worthwhile conversation to initiate at your next appointment.
